Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
The omicron variant of SARS-CoV-2 has been reported in Shanghai, China, since March
2022. In two months, the emergence of the omicron variant has resulted in 600 000 …
2022. In two months, the emergence of the omicron variant has resulted in 600 000 …
The role of antiviral treatment in the COVID-19 pandemic
TK Burki - The Lancet Respiratory Medicine, 2022 - thelancet.com
On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis
R Najjar-Debbiny, N Gronich, G Weber… - Clinical infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the …
Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody)
with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients …
with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
The global COVID-19 treatment divide
AD Usher - The Lancet, 2022 - thelancet.com
The brutal logic that has divided the world into vaccine haves and havenots is now being
repeated as gamechanging COVID-19 drugs like Pfizer's oral antiviral Paxlovid (nirmatrelvir …
repeated as gamechanging COVID-19 drugs like Pfizer's oral antiviral Paxlovid (nirmatrelvir …
[HTML][HTML] Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
AR Falsey, ME Sobieszczyk, I Hirsch… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …